A more effective shingles vaccine is expected to become available in South Africa by the end of June 2026. However, its price and planned private-sector launch could place it beyond the reach of many patients. Shingrix is manufactured by pharmaceutical company GlaxoSmithKline, or GSK. The South African Health Products Regulatory Authority recently registered the vaccine. SAHPRA registration means Shingrix can…